Last reviewed · How we verify
IMULDOSA (USTEKINUMAB-SRLF)
IMULDOSA (generic name: USTEKINUMAB-SRLF) is a drug developed by ACCORD BIOPHARMA INC.. It is currently FDA-approved.
IMULDOSA is an interleukin-12 inhibitor, classified as an antibody drug. It is also known by the synonyms CNTO 1275, CNTO-1275, PYZCHIVA, SELARSDI, STELARA, and STELERA.
At a glance
| Generic name | USTEKINUMAB-SRLF |
|---|---|
| Sponsor | ACCORD BIOPHARMA INC. |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Infections
- Cellulitis
- Herpes zoster
- Diverticulitis
- Injection site pain
- Injection site swelling
- Injection site pruritus
- Injection site induration
- Injection site hemorrhage
- Injection site bruising
- Injection site irritation
Serious adverse events
- Serious infections
- Malignancies (excluding non-melanoma skin cancer)
- Non-melanoma skin cancer
- PRES (Posterior Reversible Encephalopathy Syndrome)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMULDOSA CI brief — competitive landscape report
- IMULDOSA updates RSS · CI watch RSS
- ACCORD BIOPHARMA INC. portfolio CI
Frequently asked questions about IMULDOSA
What is IMULDOSA?
IMULDOSA (USTEKINUMAB-SRLF) is a pharmaceutical drug developed by ACCORD BIOPHARMA INC..
Who makes IMULDOSA?
IMULDOSA is developed and marketed by ACCORD BIOPHARMA INC. (see full ACCORD BIOPHARMA INC. pipeline at /company/accord-biopharma-inc).
What is the generic name of IMULDOSA?
USTEKINUMAB-SRLF is the generic (nonproprietary) name of IMULDOSA.
What development phase is IMULDOSA in?
IMULDOSA is FDA-approved (marketed).
What are the side effects of IMULDOSA?
Common side effects of IMULDOSA include Infections, Cellulitis, Herpes zoster, Diverticulitis, Injection site pain, Injection site swelling. Serious adverse events: Serious infections, Malignancies (excluding non-melanoma skin cancer), Non-melanoma skin cancer, PRES (Posterior Reversible Encephalopathy Syndrome).
Related
- Manufacturer: ACCORD BIOPHARMA INC. — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing